secwatch.observer — SEC 8-K summary
======================================

Issuer:     LABCORP HOLDINGS INC. (LH)
CIK:        0000920148
Form:       8-K
Filed at:   2023-02-16T23:59:59+00:00
Accession:  0000920148-23-000012
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Labcorp reports Q4 2022 revenue $3.7B, GAAP EPS $0.86 (vs $5.75 YoY), provides FY2023 adjusted EPS guidance $16-$18
--------------------------------------------------------------------------------

- Q4 rev $3.67B (-9.4% YoY); GAAP diluted EPS $0.86 vs $5.75; adj EPS $4.14 vs $6.77.
- Full-year 2022 rev $14.88B (-7.7%); adj EPS $19.94 vs $28.52; free cash flow $1.47B.
- Diagnostics base business organic +6.4%; Drug Development backlog $16.3B (+8.9%), net book-to-bill 1.27.
- FY2023 guidance: total rev growth 1-4%, base business 8.5-10.5%; adj EPS $16-$18; FCF $1.0-$1.2B.
- Spin-off of Clinical Development (Fortrea) on track for mid-2023; Board authorized additional $1B share buyback; $0.72 dividend payable Mar 13.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/920148/000092014823000012/0000920148-23-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/920148/000092014823000012/lh-20230216.htm
  HTML page:      https://secwatch.observer/filing/0000920148-23-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer